The SGLT-2 inhibitor (sodium-glucose cotransporter 2) dapagliflozin counteracts progression of heart failure and death of cardiovascular cause in heart failure patients with impaired left ventricular function, regardless of diabetes status. SGLT-2 inhibitors are currently approved for the treatment of type-II diabetes mellitus.

https://www.gelbe-liste.de/kardiologie/dapagliflozin-herzinsuffizienz